Literature DB >> 15827167

Cross-reactive cytotoxic T lymphocytes against human immunodeficiency virus type 1 protease and gamma interferon-inducible protein 30.

R D Mason1, M I Bowmer, C M Howley, M D Grant.   

Abstract

The gamma interferon (IFN-gamma)-inducible protein 30 (IP-30) signal peptide -11 to -3 (LLDVPTAAV) is a prominent self peptide expressed with the class I human histocompatibility leukocyte antigen A2 (HLA-A2). Stimulation of peripheral blood mononuclear cells (PBMC) from HLA-A2 human immunodeficiency virus type 1 (HIV-1)-infected individuals with an HLA-A2-restricted HIV protease (PR) peptide 76-84 (LVGPTPVNI) activated cytotoxic T lymphocytes (CTL) against the IP-30 signal peptide. Since HIV-1 PR 76-84 stimulated CD8+ T cells from these individuals to secrete IFN-gamma, we tested whether the activation of IP-30-specific CTL in vitro resulted from T-cell cross-reactivity or from up-regulation of IP-30 by IFN-gamma. Neither high levels of exogenous IFN-gamma nor incubation of PBMC with other HIV peptides triggering substantial IFN-gamma release activated IP-30-specific CTL. Although the IP-30 signal peptide did not stimulate IFN-gamma release from freshly isolated PBMC, it activated CTL in vitro against itself and HIV PR 76-84. Peptide-stimulated IFN-gamma release, cold target inhibition, and HLA-A2/immunoglobulin dimer-mediated binding and depletion of effector cells all indicated that in vitro stimulation with HIV PR 76-84 or the IP-30 signal peptide activated a comparable population of cross-reactive effector cells. Neither IP-30 nor HIV PR 76-84 activated CTL against themselves following in vitro stimulation of PBMC from non-HIV-infected HLA-A2 individuals. Peptide titrations indicated higher-avidity T-cell interactions with HIV PR 76-84 than with the IP-30 signal peptide. These data indicate that HIV PR 76-84 is a heteroclitic variant of the IP-30 signal peptide -11 to -3, which has implications for immune memory and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827167      PMCID: PMC1082750          DOI: 10.1128/JVI.79.9.5529-5536.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Intracellular formation and cell surface expression of a complex of an intact lysosomal protein and MHC class II molecules.

Authors:  B Arunachalam; M Pan; P Cresswell
Journal:  J Immunol       Date:  1998-06-15       Impact factor: 5.422

2.  Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies.

Authors:  K Murata; M C Dalakas
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

3.  Isolation and rapid identification of an abundant self-peptide from class II HLA-DRB1*0401 alleles induced by measles vaccine virus infection.

Authors:  I G Ovsyannikova; K L Johnson; S Naylor; G A Poland
Journal:  J Immunol Methods       Date:  2000-12-01       Impact factor: 2.303

4.  Defective antigen processing in GILT-free mice.

Authors:  M Maric; B Arunachalam; U T Phan; C Dong; W S Garrett; K S Cannon; C Alfonso; L Karlsson; R A Flavell; P Cresswell
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

5.  Detection of a vigorous HIV-1-specific cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS dementia complex.

Authors:  C Jassoy; R P Johnson; B A Navia; J Worth; B D Walker
Journal:  J Immunol       Date:  1992-11-01       Impact factor: 5.422

6.  EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis.

Authors:  A C van Sechel; J J Bajramovic; M J van Stipdonk; C Persoon-Deen; S B Geutskens; J M van Noort
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

7.  Functional genomic analysis of the response of HIV-1-infected lymphatic tissue to antiretroviral therapy.

Authors:  Qingsheng Li; Timothy Schacker; John Carlis; Gregory Beilman; Phuong Nguyen; Ashley T Haase
Journal:  J Infect Dis       Date:  2004-02-05       Impact factor: 5.226

8.  Cutting edge: class I presentation of host peptides following HIV infection.

Authors:  Heather D Hickman; Angela D Luis; Wilfried Bardet; Rico Buchli; Casey L Battson; Michael H Shearer; Kenneth W Jackson; Ronald C Kennedy; William H Hildebrand
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

9.  Cross-reactivity between HLA-A2-restricted FLU-M1:58-66 and HIV p17 GAG:77-85 epitopes in HIV-infected and uninfected individuals.

Authors:  Paula M Acierno; Danforth A Newton; Edwin A Brown; Lou Anne Maes; John E Baatz; Sebastiano Gattoni-Celli
Journal:  J Transl Med       Date:  2003-08-14       Impact factor: 5.531

10.  Heteroclitic immunization induces tumor immunity.

Authors:  R Dyall; W B Bowne; L W Weber; J LeMaoult; P Szabo; Y Moroi; G Piskun; J J Lewis; A N Houghton; J Nikolić-Zugić
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more
  7 in total

Review 1.  Cross-reactivity of T cells and its role in the immune system.

Authors:  Galina Petrova; Andrea Ferrante; Jack Gorski
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

2.  Cross-Reactivity against Multiple HIV-1 Epitopes Is Characteristic of HIV-1-Specific Cytotoxic T Lymphocyte Clones.

Authors:  Arumugam Balamurugan; Hwee L Ng; Otto O Yang
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

3.  Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals.

Authors:  Adam J Ritchie; Suzanne L Campion; Jakub Kopycinski; Zoe Moodie; Z Maggie Wang; Kruti Pandya; Stephen Moore; Michael K P Liu; Simon Brackenridge; Kristin Kuldanek; Kenneth Legg; Myron S Cohen; Eric L Delwart; Barton F Haynes; Sarah Fidler; Andrew J McMichael; Nilu Goonetilleke
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

4.  Greater frequency of CD5-negative CD8(+) T cells against human immunodeficiency virus type 1 than other viruses is consistent with adaptation to antigenic variation.

Authors:  Stephen J Penney; Maureen E Gallant; Michael D Grant
Journal:  AIDS Res Ther       Date:  2014-09-15       Impact factor: 2.250

5.  Private rare deletions in SEC16A and MAMDC4 may represent novel pathogenic variants in familial axial spondyloarthritis.

Authors:  Darren D O'Rielly; Mohammed Uddin; Dianne Codner; Michael Hayley; Jiayi Zhou; Lourdes Pena-Castillo; Ahmed A Mostafa; S M Mahmudul Hasan; William Liu; Nigil Haroon; Robert Inman; Proton Rahman
Journal:  Ann Rheum Dis       Date:  2015-05-08       Impact factor: 19.103

Review 6.  Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic Peptides.

Authors:  Adeolu Oyemade Adegoke; Michael David Grant
Journal:  Front Immunol       Date:  2015-07-23       Impact factor: 7.561

7.  A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.

Authors:  Lesa M Dawson; Kerri N Smith; Salem Werdyani; Robyn Ndikumana; Cindy Penney; Louisa L Wiede; Kendra L Smith; Justin A Pater; Andrée MacMillan; Jane Green; Sheila Drover; Terry-Lynn Young; Darren D O'Rielly
Journal:  Mol Genet Genomic Med       Date:  2019-11-28       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.